Drugs that contain Everolimus
1. Afinitor patents expiration
AFINITOR's oppositions filed in EPO
AFINITOR Litigations
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5665772 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004973 | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(7 years ago) | |
|
US6004973 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(7 years ago) | |
| US7741338 | NOVARTIS | Macrolides |
Dec, 2019
(4 years ago) | |
| US7297703 | NOVARTIS | Macrolides |
Dec, 2019
(4 years ago) | |
|
US5665772 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(4 years ago) | |
|
US7297703 (Pediatric) | NOVARTIS | Macrolides |
Jun, 2020
(3 years ago) | |
| US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(2 years ago) | |
| US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(2 years ago) | |
|
US8778962 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 8 months ago) | |
|
US8436010 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 7 months ago) | |
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(1 year, 6 months from now) | |
|
US8410131 (Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(2 years from now) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-724) | Feb 26, 2019 |
| Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
| Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-630) | Oct 29, 2013 |
| New Indication(I-655) | Jul 20, 2015 |
| New Indication(I-650) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Pediatric Exclusivity(PED) | Oct 26, 2015 |
| New Indication(I-638) | May 05, 2014 |
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of ...
Dosage: TABLET;ORAL
How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage
AFINITOR family patents
2. Afinitor Disperz patents expiration
AFINITOR DISPERZ's oppositions filed in EPO
Can you believe AFINITOR DISPERZ received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5665772 | NOVARTIS PHARM | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004973 | NOVARTIS PHARM | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(7 years ago) | |
|
US6004973 (Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(7 years ago) | |
| US7297703 | NOVARTIS PHARM | Macrolides |
Dec, 2019
(4 years ago) | |
|
US5665772 (Pediatric) | NOVARTIS PHARM | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(4 years ago) | |
|
US7297703 (Pediatric) | NOVARTIS PHARM | Macrolides |
Jun, 2020
(3 years ago) | |
| US8778962 | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(2 years ago) | |
|
US8778962 (Pediatric) | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 8 months ago) | |
| US8617598 | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Sep, 2022
(1 year, 6 months ago) | |
|
US8617598 (Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Mar, 2023
(1 year, 24 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-169) | Apr 10, 2025 |
| New Indication(I-773) | Apr 10, 2021 |
| Pediatric Exclusivity(PED) | Apr 29, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-630) | Oct 29, 2013 |
NCE-1 date: 29 April, 2017
Market Authorisation Date: 29 August, 2012
Treatment: Adjunctive treatment of patients with tsc-associated partial-onset seizures
Dosage: TABLET, FOR SUSPENSION;ORAL
How can I launch a generic of AFINITOR DISPERZ before it's drug patent expiration?
More Information on Dosage
AFINITOR DISPERZ family patents
3. Zortress patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5665772 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6440990 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2013
(10 years ago) | |
|
US6440990 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2014
(10 years ago) | |
| US6004973 | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(7 years ago) | |
|
US6004973 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(7 years ago) | |
| US6239124 | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
Jul, 2017
(6 years ago) | |
| US6455518 | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Jul, 2017
(6 years ago) | |
|
US6239124 (Pediatric) | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
Jan, 2018
(6 years ago) | |
|
US6455518 (Pediatric) | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Jan, 2018
(6 years ago) | |
|
US5665772 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 20, 2013 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-668) | Feb 15, 2016 |
| Pediatric Exclusivity(PED) | Oct 20, 2013 |
NCE-1 date: 30 September, 2013
Market Authorisation Date: 20 April, 2010
Treatment: Prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a renal transplant
Dosage: TABLET;ORAL
How can I launch a generic of ZORTRESS before it's drug patent expiration?
More Information on Dosage
ZORTRESS family patents